The Connection Between Neurodegenerative Disease and The Law

April 17, 2018

[vc_row][vc_column][vc_column_text margin_bottom=”5″ css=”.vc_custom_1525900113064{margin-bottom: 0px !important;}”]The first wave of baby boomers have hit the age of 65, when the risk of Alzheimer’s significantly increases. It is estimated that 10 million members of this generation will contract the disease, according to the Alzheimer’s Association, and of those to reach the age of 85, close to one in two will be diagnosed with it. These numbers don’t take into account the other cases of dementia. While doctors and scientist scramble to develop a cure and treatment to slow the progression of the disease, a health crisis of epic proportions unfolds before us.

When dealing with dementia-related diagnosis, one area that is often left unexplored is the effect these conditions have on will contests and the courts. Often times in a will contest, the issue of dementia is a major linchpin as the plaintiff doesn’t believe the deceased had the mental capacity to create the will in dispute. If they have suffered from Alzheimer’s or another neurodegenerative disease, there may be a case under probate law to invalidate the will.Historically courts have failed to recognize the differences among neurodegenerative disorders and their unique incapacities and often leave them unspecified in case law. This is particularly problematic to understanding the true intentions of the will and the progression of decline for each specific type of dementia.

As a lawyer specializing in wills and trusts, it is Jimmy Carter’s passion project to not only educate the public about the perniciousness of these conditions, but to challenge the way courts view dementia by researching and analyzing the intersection of law and neurodegenerative deficits that occur alongside aging.[/vc_column_text][mk_blockquote style=”line-style” font_family=”none”]“Protecting the true intentions of a loved one is a serious job in probate court. If the system ignores the latest medical science, then it may also be ignoring its pivotal role for beneficiaries.”[/mk_blockquote][vc_column_text margin_bottom=”5″ css=”.vc_custom_1525141663356{margin-bottom: 0px !important;}”]In that vein, this blog aims to provide the public with information on the varying degrees and forms of dementia through frank discussions about their different biological impacts and symptoms, and most importantly here, how these conditions can potentially affect a will. Over the next few weeks, this series will explore the differences among the four common types of dementia: Alzheimer’s Disease, Vascular Dementia, Dementia with Lewy Body and Frontotemporal Dementia.

It is our aim to educate the public about these diseases so that anyone faced with these circumstances are better equipped to respond to situations as they arise. We also hope to provide all with valuable resources and information that will aid in navigating this tricky territory with aging family members.
[/vc_column_text][/vc_column][/vc_row]

Other Articles

  • Breakthrough: Blood Test Makes it Possible to Track Alzheimer’s Advancement 
    A connection between Neurofilament light (NfL) levels present in the blood and Alzheimer’s disease was recently made in a study released by the JAMA Network.
  • New Study Might Diagnose CTE in Brains of the Living
    A recent study published in the New England Journal of medicine revealed that brain scans of more than two dozen former NFL players found that the men had abnormal levels of the protein linked to chronic traumatic encephalopathy (C.T.E.), the degenerative brain disease we have discussed here that’s associated with repeated hits to the head.  
  • JUST PUT DOWN THE SUPPLEMENTS 
    There have long been debates among established medical authorities and supplement manufacturers, especially when it comes to treating cognitive decline. Are the myriad of supplements currently on the market a genie in a bottle? Or is it better to focus on leading a healthy, balanced lifestyle? 
  • BREAKING NEWS: Promising Alzheimer’s Drug Fails in Late-Stage Human Trials 
    Another big blow came to the Alzheimer’s research community late last month when pharmaceutical company Biogen and Eisai Co. announced on March 22 that they would terminate two late-stage studies of
  • Could a Noninvasive Eye Exam Preemptively Diagnose Alzheimer’s Disease? 
    That’s what a recent study conducted at the Duke Eye Center suggests. The study of more than 200 people, published on March 11 in the journal Ophthalmology Retina, proposes that a quick, noninvasive
  • Tom Seaver Diagnosis Reignites Lyme Disease & Dementia Debate
    AN ARTICLE IN The New York Times recently revealed that Tom Seaver, legendary pitcher and the most prominent player in New York Mets history, is stepping back from public life because of advancing dementia. It was recently discovered that Seaver, 74, has dementia. However, for many years he suffered from the effects of Lyme disease, which can cause cognitive problems similar to dementia.